Thyrocare Technologies Limited
NSE: THYROCARE BSE: THYROCARE
Prev Close
1350.5
Open Price
1357.5
Volume
325,459
Today Low / High
1350.6 / 1435
52 WK Low / High
658 / 1435
Range
1,307 - 1,445
Prev Close
1349.5
Open Price
1366
Volume
11,549
Today Low / High
1353 / 1434.3
52 WK Low / High
658 / 1434.3
Range
1,309 - 1,447
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1376.2 (target range: 1,307 - 1,445), reflecting a change of 25.7 (1.903%). On the BSE, it is listed at 1377.75 (target range: 1,309 - 1,447), showing a change of 28.25 (2.09337%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Thyrocare Technologies Limited Graph
Thyrocare Technologies Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Thyrocare Technologies Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,376.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,377.75 | 1,391.53 | 1,252.37 - 1,530.68 |
| 1,405.31 | 1,124.24 - 1,686.37 | ||
| 1,419.08 | 993.36 - 1,844.81 | ||
| Bearish Scenario | 1,377.75 | 1,363.97 | 1,227.58 - 1,500.37 |
| 1,350.20 | 1,080.16 - 1,620.23 | ||
| 1,336.42 | 935.49 - 1,737.34 |
Overview of Thyrocare Technologies Limited
ISIN
INE594H01019
Industry
Medical - Diagnostics & Research
Vol.Avg
137,823
Market Cap
72,056,485,680
Last Dividend
39
Official Website
IPO Date
2016-05-10
DCF Diff
-1,735.37
DCF
3,086
Financial Ratios Every Investor Needs
Stock Dividend of THYROCARE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 21 | 21 | 2025-07-25 | 2025-08-30 | |
| 2024-08-16 | August 16, 24 | 18 | 18 | 2024-08-16 | 2024-09-22 | |
| 2023-04-20 | April 20, 23 | 18 | 18 | 2023-04-20 | 2023-04-29 | |
| 2022-05-11 | May 11, 22 | 15 | 15 | 2022-05-12 | 2022-05-29 | |
| 2021-06-17 | June 17, 21 | 15 | 15 | 2021-06-18 | 2021-07-26 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 687.35 Cr | 191.08 Cr | 496.27 Cr | 0.7220 | 0.00 Cr | 37.12 Cr | 135.10 Cr | 91.51 Cr | 17.28 | 205.19 Cr | 0.1331 |
| 2024-03-31 | 571.88 Cr | 391.07 Cr | 180.81 Cr | 0.3162 | 0.00 Cr | 33.01 Cr | 92.71 Cr | 70.76 Cr | 13.42 | 148.13 Cr | 0.1237 |
| 2023-03-31 | 526.67 Cr | 163.23 Cr | 363.44 Cr | 0.6901 | 0.00 Cr | 23.35 Cr | 86.55 Cr | 64.49 Cr | 12.16 | 130.95 Cr | 0.1224 |
| 2022-03-31 | 588.86 Cr | 169.69 Cr | 419.17 Cr | 0.7118 | 0.00 Cr | 17.38 Cr | 201.02 Cr | 176.14 Cr | 33.30 | 264.14 Cr | 0.2991 |
| 2021-03-31 | 494.62 Cr | 163.90 Cr | 330.72 Cr | 0.6686 | 0.00 Cr | 13.35 Cr | 141.12 Cr | 113.15 Cr | 21.41 | 183.69 Cr | 0.2288 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 17.68 Cr | 692.75 Cr | 145.70 Cr | 546.7500 Cr | 24.68 Cr | 7.00 Cr | 73.00 Cr | 198.31 Cr | 0.00 Cr | 0.00 Cr | 24.89 Cr | 121.8400 Cr |
| 2024-03-31 | 9.30 Cr | 643.88 Cr | 116.25 Cr | 526.7700 Cr | 42.34 Cr | 33.04 Cr | 47.52 Cr | 203.70 Cr | 6.16 Cr | -1.43 Cr | 25.62 Cr | 90.4800 Cr |
| 2023-03-31 | 17.77 Cr | 632.72 Cr | 97.50 Cr | 534.3000 Cr | 23.31 Cr | 5.54 Cr | 30.23 Cr | 194.43 Cr | 36.65 Cr | 0.00 Cr | 22.10 Cr | 77.1000 Cr |
| 2022-03-31 | 13.63 Cr | 607.66 Cr | 81.09 Cr | 526.5700 Cr | 20.70 Cr | 7.07 Cr | 34.43 Cr | 186.79 Cr | 9.34 Cr | 0.00 Cr | 20.92 Cr | 64.5200 Cr |
| 2021-03-31 | 13.20 Cr | 545.80 Cr | 118.52 Cr | 427.2800 Cr | 8.49 Cr | -4.71 Cr | 24.96 Cr | 160.07 Cr | 39.85 Cr | 9.19 Cr | 21.10 Cr | 95.1000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 191.3200 Cr | -52.5200 Cr | -130.4200 Cr | 146.4300 Cr | 8.3800 Cr | 17.6800 Cr | -44.8900 Cr | 146.8800 Cr | -21.5900 Cr | -95.3100 Cr | 0.9900 Cr |
| 2024-03-31 | 167.6300 Cr | -91.2800 Cr | -84.8000 Cr | 106.0300 Cr | -8.4700 Cr | 9.3000 Cr | -61.5800 Cr | 70.7600 Cr | 21.5900 Cr | -95.2700 Cr | -19.8500 Cr |
| 2023-03-31 | 129.3100 Cr | -38.9900 Cr | -86.1800 Cr | 85.6600 Cr | 4.1400 Cr | 17.7700 Cr | -43.6500 Cr | 87.4100 Cr | -5.5300 Cr | -79.3500 Cr | -3.1400 Cr |
| 2022-03-31 | 113.4100 Cr | -23.5700 Cr | -89.4100 Cr | 75.5800 Cr | 0.4300 Cr | 13.6300 Cr | -37.8300 Cr | 227.9000 Cr | -5.3800 Cr | -79.3100 Cr | -1.1700 Cr |
| 2021-03-31 | 116.0300 Cr | -50.2300 Cr | -61.5700 Cr | 87.7700 Cr | 4.2400 Cr | 13.2000 Cr | -28.2600 Cr | 152.5400 Cr | -2.5000 Cr | -52.8400 Cr | -2.7400 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 193.03 Cr | 55.63 Cr | 137.40 Cr | 0.7118 | 46.36 Cr | 38.98 Cr | 7.35 | 62.67 Cr | 0.2019 |
| 2025-03-31 | 187.16 Cr | 82.94 Cr | 104.22 Cr | 0.5568 | 43.93 Cr | 21.70 Cr | 4.17 | 57.75 Cr | 0.1159 |
| 2024-12-31 | 165.92 Cr | 45.16 Cr | 120.76 Cr | 0.7278 | 24.67 Cr | 19.11 Cr | 3.58 | 45.74 Cr | 0.1152 |
| 2024-09-30 | 177.36 Cr | 93.55 Cr | 83.81 Cr | 0.4725 | 35.22 Cr | 26.67 Cr | 4.99 | 50.61 Cr | 0.1504 |
| 2024-06-30 | 156.91 Cr | 85.54 Cr | 71.37 Cr | 0.4548 | 31.28 Cr | 24.17 Cr | 4.56 | 46.26 Cr | 0.1540 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 17.68 Cr | 173.99 Cr | 192.99 Cr | 46.54 Cr | 73.00 Cr | 337.72 Cr | 198.31 Cr | 692.75 Cr | 145.70 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 137.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -488.67 Cr |
| 2024-09-30 | 54.05 Cr | 83.51 Cr | 137.56 Cr | 47.93 Cr | 44.07 Cr | 244.84 Cr | 187.26 Cr | 597.08 Cr | 108.41 Cr |
| 2024-06-30 | -179.96 Cr | 359.92 Cr | 179.96 Cr | 0.00 Cr | 0.00 Cr | 179.96 Cr | 0.00 Cr | 0.00 Cr | -527.63 Cr |
| 2024-03-31 | 39.89 Cr | 167.33 Cr | 176.64 Cr | 44.16 Cr | 47.52 Cr | 278.51 Cr | 203.71 Cr | 643.88 Cr | 116.25 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 21.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 19.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 26.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 24.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 17.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 9.30 Cr | 41.61 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Diagnostics & Research
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Dr. Lal PathLabs Limited | LALPATHLAB | ₹3,295.40 | ₹275,334,090,625.00 | ₹98,392.00 |
| Metropolis Healthcare Limited | METROPOLIS | ₹2,125.60 | ₹110,110,118,640.00 | ₹119,608.00 |
| Vijaya Diagnostic Centre Limited | VIJAYA | ₹1,058.00 | ₹108,642,962,380.00 | ₹83,492.00 |
| Thyrocare Technologies Limited | THYROCARE | ₹1,376.20 | ₹72,930,893,280.00 | ₹325,459.00 |
| Vimta Labs Limited | VIMTALABS | ₹660.40 | ₹29,391,498,240.00 | ₹2,159,159.00 |
| Krsnaa Diagnostics Limited | KRSNAA | ₹798.05 | ₹25,887,680,594.00 | ₹66,333.00 |
Key Executives
Gender: female
Year Born: 1983
Gender: male
Year Born: 1989
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1978
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Thyrocare Technologies Limited
The CEO is Rahul Franklin Guha.
The current price is ₹1,359.70.
The range is ₹658-1435.
The market capitalization is ₹7,205.65 crores.
The dividend yield is 2.87%.
The P/E ratio is 67.73.
The company operates in the Healthcare sector.
Overview of Thyrocare Technologies Limited (ISIN: INE594H01019) is a leading Medical - Diagnostics & Research in India. With a market capitalization of ₹7,205.65 crores and an average daily volume of 137,823 shares, it operates in the Medical - Diagnostics & Research. The company last declared a dividend of ₹39.